The finnish diabetes risk score (FINDRISC) as a screening tool for hepatic steatosis

Annals of Medicine

Volumn 43, Issue 6, 2011, Pages 487-494

  Carvalho, José A M ^a   Barengo, Noël C ^b,c   Tuomilehto, Jaakko ^c,d,e   Conceição, Raquel D ^a   Santos, Raul D ^a,f  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b Fund Para la Prevenciony Control de Las Enfermedades Cronicas No Transmisibles en America Latina   (Argentina)

^c UNIVERSITY OF HELSINKI   (Finland)

^d SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Non alcoholic fatty liver disease; Obesity; Screening; Steatosis; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; FATTY LIVER; FEMALE; FINNISH DIABETES RISK SCORE; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCREENING TEST; ULTRASOUND; WAIST CIRCUMFERENCE;

ADULT; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTORS; ROC CURVE; SEX FACTORS;

EID: 79960159345     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.554428     Document Type: Article

References (26)

1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:141-50.
2. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non- alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18:1089-104. (Pubitemid 39517694)
3. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634-42. (Pubitemid 40591217)
4. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537-44.
5. Joseph AEA, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonog-raphy in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26-31.
6. Ahmeda MH, Abua EO, Byrne CD. Non-alcoholic fatty liver disease (NAFLD): New challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129-37.
7. Lindstr ö m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26: 725-31. (Pubitemid 36929335)
8. Saaristo T, Peltonen M, Lindstr ö m J, Saarikoski L, Sundvall J, Eriksson JG, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2:67-72. (Pubitemid 40826998)
9. Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187-94. (Pubitemid 40616633)
10. Ryd é n L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28: 88-136. (Pubitemid 46137814)
11. Silventoinen K, Pankow J, Lindstr ö m J, Jousilahti P, Hu G, Tuomilehto J. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005;12:451-8. (Pubitemid 44966789)
12. Schwarz PE, Li J, Reimann M, Schutte AE, Bergmann A, Hanefeld M, et al. The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. J Clin Endocrinol Metab. 2009;94:920-6.
13. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789-95. (Pubitemid 28421422)
14. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphyg-momanometry. Circulation. 1993;88 (5 Pt 1):2460-70.
15. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104;1694-740. (Pubitemid 32947537)
16. Bellentani S, Saccoccio G, Masutti F, Croc è LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic stea-tosis in Northern Italy. Ann Intern Med. 2000;132:112-7. (Pubitemid 30044177)
17. Kahn SH. The ' lipid accumulation product ' performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
18. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
19. Bailey SM, Mantena SK, Millender-Swain T, Cakir Y, Jhala NC, Chieng D, et al. Ethanol and tobacco smoke increase hepatic steatosis and hypoxia in the hypercholesterolemic apoE(-/-) mouse: implications for a ' multihit ' hypothesis of fatty liver disease. Free Radic Biol Med. 2009;46:928-38.
20. Bradley KA, Boyd-Wickizer J, Powell SH, Burman ML. Alcohol screening questionnaires in women: a critical review. JAMA. 1998;280:166-71. (Pubitemid 28498390)
21. Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399-402. (Pubitemid 37296170)
22. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
23. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000-4. (Pubitemid 37430103)
24. Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010;209:481-6.
25. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fi brosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7: 1104-12.
26. Lindstr ö m J, Peltonen M, Eriksson JG, Aunola S, H ä m ä l ä inen H, Ilanne-Parikka P, et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31:857-62.